Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
Medicinal Research Reviews · 2023
DOI: 10.1002/med.21970 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2023. Verfasst von Yujie Pu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Cardiovascular System. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 212 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee.
Abstract (Originalsprache)
The prevalence of cardiovascular disease (CVD) has been rising due to sedentary lifestyles and unhealthy dietary patterns. Peroxisome proliferator‐activated receptor α (PPARα) is a nuclear receptor regulating multiple biological processes, such as lipid metabolism and inflammatory response critical to cardiovascular homeostasis. Healthy endothelial cells (ECs) lining the lumen of blood vessels maintains vascular homeostasis, where endothelial dysfunction associated with increased oxidative stress and inflammation triggers the pathogenesis of CVD. PPARα activation decreases endothelial inflammation and senescence, contributing to improved vascular function and reduced risk of atherosclerosis. Phenotypic switch and inflammation of vascular smooth muscle cells (VSMCs) exacerbate vascular dysfunction and atherogenesis, in which PPARα activation improves VSMC homeostasis. Different immune cells participate in the progression of vascular inflammation and atherosclerosis. PPARα in immune cells plays a critical role in immunological events, such as monocyte/macrophage adhesion and infiltration, macrophage polarization, dendritic cell (DC) embedment, T cell activation, and B cell differentiation. Cardiomyocyte dysfunction, a major risk factor for heart failure, can also be alleviated by PPARα activation through maintaining cardiac mitochondrial stability and inhibiting cardiac lipid accumulation, oxidative stress, inflammation, and fibrosis. This review discusses the current understanding and future perspectives on the role of PPARα in the regulation of the cardiovascular system as well as the clinical application of PPARα ligands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Institute for Cardiovascular Development and Regenerative Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Faculty of Medicine, Macau University of Science & Technology, Macau, China.
ORCID-Profile: Yu Huang
Förderung
- Research Grants Council, University Grants Committee
Zitieren
APA
Pu, Y., Cheng, C. K., Zhang, H., Luo, J. Y., Wang, L., Tomlinson, B., & Huang, Y. (2023). Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease. Medicinal Research Reviews. https://doi.org/10.1002/med.21970
Vancouver
Pu Y, Cheng CK, Zhang H, Luo JY, Wang L, Tomlinson B, et al. Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease. Medicinal Research Reviews. 2023. doi:10.1002/med.21970
BibTeX
@article{Pu2023,
author = {Pu, Yujie and Cheng, Chak Kwong and Zhang, Hongsong and Luo, Jiang-Yun and Wang, Li and Tomlinson, Brian and Huang, Yu},
title = {Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease},
journal = {Medicinal Research Reviews},
year = {2023},
doi = {10.1002/med.21970}
}
EUVIMED